Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

Wang, Zhijie; Duan, Jianchun; Cai, Shangli; Han, Miao; Dong, Hua; Zhao, Jun; Zhu, Bo; Wang, Shuhang; Zhuo, Minglei; Sun, Jianguo; Wang, Qiming; Bai, Hua; Han, Jiefei; Tian, Yanhua; Lü, Jing; Xu, Tongfu; Zhao, Xiaochen; Wang, Guoqiang; Cao, Xinkai; Li, Fugen; Wang, Dalei; Chen, Yuejun; Bai, Yuezong; Zhao, Jing; Zhao, Zhengyi; Zhang, Yuzi; Xiong, Lei; He, Jie; Gao, Shugeng; Wang, Jie

doi:10.1001/jamaoncol.2018.7098

Public

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

Published in JAMA Oncology • Feb 28, 2019

Authors:

Zhijie Wang

Jianchun Duan

Shangli Cai

Abstract

IMPORTANCE: Tumor mutational burden (TMB), as measured by whole-exome sequencing (WES) or a cancer gene panel (CGP), is associated with immunotherapy responses. However, whether TMB estimated by circulating tumor DNA in blood (bTMB) is associated with clinical outcomes of immunotherapy remains to be...

Subject

Medicine

Lung cancer

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!